Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Patritumab Deruxtecan
Sponsor: Daiichi Sankyo Co., Ltd.
Collaborators: Daiichi Sankyo